甲状旁腺素、降钙素和阿仑膦酸钠治疗绝经后妇女骨质疏松症的疗效比较

被引：6

作者：

陈成旺

潘孝云

薛恩兴

温宏

机构：

[1] 温州医科大学附属第二医院骨科

来源：

温州医学院学报 | 2013年 / 10期

关键词：

甲状旁腺素; 降钙素; 阿仑膦酸钠; 骨密度; 骨质疏松症;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

目的:比较甲状旁腺素、鲑降钙素、阿仑膦酸钠对绝经后妇女骨质疏松症的疗效。方法:对110位确诊患有骨质疏松症的绝经后妇女进行随机分组,分别接受甲状旁腺素20μg/d皮下注射(36例)或鲑降钙素200 IU/d鼻内给药(36例)或阿仑膦酸钠70 mg/周口服(38例),共24周。测定主要指标为从基线到终点腰椎骨密度(BMD)变化量;次要指标为从基线到终点全髋BMD变化量及血清骨钙素含量的变化。对结果进行分析比较。结果:共100例患者完成治疗,10例患者中途退出研究。甲状旁腺素组(n=36)在增加患有骨质疏松症的绝经后中国妇女腰椎BMD及血清骨钙素含量方面明显优于降钙素组(n=31)及阿仑膦酸钠组(n=33),在改变全髋BMD方面与降钙素组及阿仑膦酸钠组无明显差别。结论:与降钙素及阿仑膦酸钠相比,甲状旁腺素在促进患有骨质疏松症的绝经后妇女的骨形成方面的效果更佳。

引用

页码：670 / 673

页数：4

共 9 条

[1]

特立帕肽与阿仑膦酸盐对比治疗骨质疏松症有效性及安全性的Meta分析 [J].

李丹 ;

陈兴明 ;

乔凤娟 ;

敬华 .

中国骨质疏松杂志, 2011, 17 (11) :997-1001

[2]

Teriparatide Accelerates Lumbar Posterolateral Fusion in Women With Postmenopausal Osteoporosis: Prospective Study[J] Seiji Ohtori;Gen Inoue;Sumihisa Orita;Kazuyo Yamauchi;Yawara Eguchi;Nobuyasu Ochiai;Shunji Kishida;Kazuki Kuniyoshi;Yasuchika Aoki;Junichi Nakamura;Tetsuhiro Ishikawa;Masayuki Miyagi;Hiroto Kamoda;Miyako Suzuki;Gou Kubota;Yoshihiro Sakuma;Yasuhiro Oikawa;Kazuhide Inage;Takeshi Sainoh;Masashi Takaso;Tomoyuki Ozawa;Kazuhisa Takahashi;Tomoaki Toyone Spine 2012,

[3]

Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS)[J] J. Walsh;Willem Lems;Dimitrios Karras;Bente Langdahl;Osten Ljunggren;Astrid Fahrleitner-Pammer;Annabel Barrett;Gerald Rajzbaum;Franz Jakob;Fernando Marin Calcified Tissue International 2012,

[4]

Rapid and robust response of biochemical markers of bone formation to teriparatide therapy[J] Sarah J. Glover;Richard Eastell;Eugene V. McCloskey;Angela Rogers;Patrick Garnero;Jonathan Lowery;Rossella Belleli;Timothy M. Wright;Markus R. John Bone 2009,

[5]

Preventing Osteoporosis-Related Fractures: An Overview[J] Margery Gass;Bess Dawson-Hughes The American Journal of Medicine 2006,

[6]

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6‐month study*[J] A. W. C. Kung;E. G. Pasion;M. Sofiyan;E. M. C. Lau;B. K. Tay;K. S. Lam;K. Wilawan;B. Ongphiphadhanakul;D. Thiebaud 2006,

[7]

Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis[J] J. S. Hwang;S. T. Tu;T. S. Yang;J. F. Chen;C. J. Wang;K. S. Tsai Osteoporosis International 2006,

[8]

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy[J] Pierre D Delmas;Ego Seeman Bone 2004,

[9]

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study[J] Charles H Chesnut;Stuart Silverman;Kim Andriano;Harry Genant;Alberto Gimona;Steven Harris;Douglas Kiel;Meryl LeBoff;Michael Maricic;Paul Miller;Caje Moniz;Munro Peacock;Peter Richardson;Nelson Watts;David Baylink The American Journal of Medicine 2000,

← 1 →